Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Antitumor treatment may increase risk of severe events in COVID-19 patients

Key clinical point: Cancer patients who received antitumor treatment within 14 days of COVID-19 diagnosis had an increased risk of severe events, defined as ICU admission, mechanical ventilation, or death.

Major finding: In a multivariable analysis, receiving antitumor treatment within 14 days was significantly associated with severe events (hazard ratio, 4.079; P = .037).

Study details: A retrospective study of 28 patients with cancer and COVID-19.

Disclosures: Dr. Zhang and colleagues reported no conflicts of interest. The research was funded by the National Natural Science Foundation of China and Huazhong University of Science and Technology COVID-19 Rapid Response Call China.


Zhang L et al. Ann Oncol. 2020 Mar 26. doi: 10.1016/j.annonc.2020.03.296.